Clinical Practice Guideline
- Identification, Evaluation, and Treatment of
Overweight and Obesity in Adults
| Topic: Identification,
Evaluation, and Treatment of Overweight
and Obesity in Adults |
Date of Origin: February
2008 |
| Revised/Effective Date: April
2009 |
Next Review Date: April
2010 |
Recommendation Summary:
Asuris supports the recommendations of
the National Heart Lung and Blood Institute
(NHLBI) and the content of the latest version
of the evidence report entitled Clinical
Guidelines on the Identification, Evaluation,
and Treatment of Overweight and Obesity in Adults.
Web Site Link:
National Heart, Lung and Blood Institute; located
at: http://www.nhlbi.nih.gov/guidelines/obesity/
Position Statement:
Asuris supports the NHLBI guidelines because
they are based on scientific evidence, and where
evidence is lacking, on expert consensus. The
strength of evidence supporting each recommendation
is clearly indicated. When there is not
good evidence, recommendations are based on expert
consensus and are clearly stated as such. The
guidelines reflect the most current standard
of care for the identification, evaluation and
management of overweight and obesity.
- The panel members are recognized experts
practicing in a variety of professional settings.
- Recommendations are based on a well-defined,
comprehensive scientific literature search.
- Methods used to select appropriate scientific
literature are well defined.
- The San Antonio Cochrane Center, a globally
recognized group of EBM experts, assisted in
preparation of the evidence tables.
- The methods used to critically appraise the
evidence supporting guideline recommendations
are transparent.
- The guidelines clearly state the strength
of the evidence for which recommendations are
based.
- 115 external reviewers from 59 government
agencies, professional societies, and consumer
groups evaluated and commented on the guideline
prior to publication.
- Sources of funding:
- Primarily NHLBI, with cooperation of
National Institute of Diabetes and Digestive
and Kidney Disease (NIDDK) of the National
Institutes of Health.
- No conflict of interest statements for
panel members are included in the evidence
report.
Guideline Adoption and Recommended
Use:
This guideline has been adopted
based on nationally recognized sources. This
guideline is based on the most recent medical
evidence or a consensus on clinical treatment
patterns by physicians in the selected field
of practice.
Asuris adopts guidelines to help practitioners
and members make decisions about appropriate
health care for specific conditions. Guidelines
are not a substitute for professional medical
advice.
The following organizations endorse
the evidence report:
- National Cholesterol Education Program (NCEP)
- National High Blood Pressure Education Program
(NHBPEP)
- NIDDK National Task Force on the Prevention
and Treatment of Obesity
- North American Association for the Study
of Obesity (NAASO)
Benefit Determination:
Benefit determinations should be based in
all cases on the applicable contract coverage.
To the extent that there are any conflicts
between these guidelines and the contract language,
the contract language will control.
Back to Index 
|
